SARS-CoV-2 infection and return to play in junior competitive athletes: is systematic cardiac screening needed?

Luna Cavigli, Michele Cillis, Veronica Mochi, Federica Frascaro, Nicola Mochi, Arnel Hajdarevic, Alessandra Roselli, Massimo Capitani, Federico Alvino, Silvia Giovani, Corrado Lisi, Maria Teresa Cappellini, Rosa Anna Colloca, Giulia Elena Mandoli, Serafina Valente, Marta Focardi, Matteo Cameli, Marco Bonifazi, Flavio D'Ascenzi
Author Information
  1. Luna Cavigli: Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy.
  2. Michele Cillis: Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy.
  3. Veronica Mochi: Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy.
  4. Federica Frascaro: Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy.
  5. Nicola Mochi: Sports Medicine Unit, USL Toscana Centro, Italy, Firenze, Italy.
  6. Arnel Hajdarevic: Medical Lab, Center for Sports Medicine and Rehabilitation, Asti, Italy.
  7. Alessandra Roselli: Institute of Sports Medicine, Firenze, Italy.
  8. Massimo Capitani: Center for Sports Medicine, National Health Service, Siena, Italy.
  9. Federico Alvino: Center for Sports Medicine, National Health Service, Siena, Italy.
  10. Silvia Giovani: Center for Sports Medicine, National Health Service, Siena, Italy.
  11. Corrado Lisi: Sports Medicine Unit, USL Toscana Centro, Italy, Firenze, Italy.
  12. Maria Teresa Cappellini: Sports Medicine Unit, USL Toscana Centro, Italy, Firenze, Italy.
  13. Rosa Anna Colloca: Sports Medicine Unit, USL Toscana Centro, Italy, Firenze, Italy.
  14. Giulia Elena Mandoli: Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy.
  15. Serafina Valente: Clinical and Surgical Cardiology Uniti, Cardiothoracic and Vascular Department, University Hospital Le Scotte, Siena, Italy.
  16. Marta Focardi: Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy.
  17. Matteo Cameli: Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy.
  18. Marco Bonifazi: Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
  19. Flavio D'Ascenzi: Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy flavio.dascenzi@unisi.it. ORCID

Abstract

BACKGROUND: SARS-CoV-2 infection might be associated with cardiac complications in low-risk populations, such as in competitive athletes. However, data obtained in adults cannot be directly transferred to preadolescents and adolescents who are less susceptible to adverse clinical outcomes and are often asymptomatic.
OBJECTIVES: We conducted this prospective multicentre study to describe the incidence of cardiovascular complications following SARS-CoV-2 infection in a large cohort of junior athletes and to examine the effectiveness of a screening protocol for a safe return to play.
METHODS: Junior competitive athletes suffering from asymptomatic or mildly symptomatic SARS-CoV-2 infection underwent cardiac screening, including physical examination, 12-lead resting ECG, echocardiogram and exercise ECG testing. Further investigations were performed in cases of abnormal findings.
RESULTS: A total of 571 competitive junior athletes (14.3±2.5 years) were evaluated. About half of the population (50.3%) was mildly symptomatic during SARS-CoV-2 infection, and the average duration of symptoms was 4±1 days. pericardial involvement was found in 3.2% of junior athletes: small pericardial effusion (2.6%), moderate pericardial effusion (0.2%) and pericarditis (0.4%). No relevant arrhythmias or myocardial inflammation was found in subjects with pericardial involvement. Athletes with pericarditis or moderate pericardial effusion were temporarily disqualified, and a gradual return to play was achieved after complete clinical resolution.
CONCLUSIONS: The prevalence of cardiac involvement was low in junior athletes after asymptomatic or mild SARS-CoV-2 infection. A screening strategy primarily driven by cardiac symptoms should detect cardiac involvement from SARS-CoV-2 infection in most junior athletes. Systematic echocardiographic screening is not recommended in junior athletes.

Keywords

MeSH Term

Adolescent
Adult
Athletes
COVID-19
Heart Diseases
Humans
Prospective Studies
Return to Sport
SARS-CoV-2

Word Cloud

Created with Highcharts 10.0.0athletesSARS-CoV-2infectionjuniorcardiacscreeningcompetitiveinvolvementpericardialasymptomaticreturnplayeffusioncomplicationsclinicalmildlysymptomaticECGsymptomsfound2%athletes:moderate0pericarditisBACKGROUND:mightassociatedlow-riskpopulationsHoweverdataobtainedadultsdirectlytransferredpreadolescentsadolescentslesssusceptibleadverseoutcomesoftenOBJECTIVES:conductedprospectivemulticentrestudydescribeincidencecardiovascularfollowinglargecohortexamineeffectivenessprotocolsafeMETHODS:Juniorsufferingunderwentincludingphysicalexamination12-leadrestingechocardiogramexercisetestinginvestigationsperformedcasesabnormalfindingsRESULTS:total571143±25yearsevaluatedhalfpopulation503%averageduration4±1 daysPericardial3small26%4%relevantarrhythmiasmyocardialinflammationsubjectsAthletestemporarilydisqualifiedgradualachievedcompleteresolutionCONCLUSIONS:prevalencelowmildstrategyprimarilydrivendetectSystematicechocardiographicrecommendedsystematicneeded?COVID-19childhealthsports

Similar Articles

Cited By